These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3577775)

  • 1. [Investigation of the selectivity of the dihydrofolate reductase inhibitor 5-substituted benzyl-2,4-diamino-pyrimidines].
    Li RL; Fang ZX
    Yao Xue Xue Bao; 1986 Oct; 21(10):753-60. PubMed ID: 3577775
    [No Abstract]   [Full Text] [Related]  

  • 2. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
    J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Vasudevan A; Queener SF
    J Med Chem; 1997 Sep; 40(19):3032-9. PubMed ID: 9301665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basis of selectivity of antibacterial diaminopyrimidines.
    Baccanari DP; Kuyper LF
    J Chemother; 1993 Dec; 5(6):393-9. PubMed ID: 8195830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
    Gangjee A; Lin X; Queener SF
    J Med Chem; 2004 Jul; 47(14):3689-92. PubMed ID: 15214795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative correlation between molar refractivity and the inhibition of dihydrofolate reductase by 2,4-diamino-5-benzylpyrimidines.
    Kumar NA; Rao MN
    Indian J Biochem Biophys; 1986 Feb; 23(1):58-60. PubMed ID: 3525396
    [No Abstract]   [Full Text] [Related]  

  • 9. On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted-benzyl)pyrimidines with dihydrofolate reductase.
    Selassie CD; Li RL; Poe M; Hansch C
    J Med Chem; 1991 Jan; 34(1):46-54. PubMed ID: 1899453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
    J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear quantitative structure-activity relationship for the inhibition of dihydrofolate reductase by pyrimidines.
    Hirst JD
    J Med Chem; 1996 Aug; 39(18):3526-32. PubMed ID: 8784450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of dihydrofolate reductase and thymidylate synthetase in strains of Streptococcus faecium resistant to substituted pyrimidines, triazines and MTX.
    Smith CC; Freisheim JH
    Ann N Y Acad Sci; 1971 Nov; 186():182-4. PubMed ID: 5002296
    [No Abstract]   [Full Text] [Related]  

  • 15. Structural studies on bio-active compounds. Part 16. Synthesis and properties of sterically-constrained analogues of methylbenzoprim, a new dihydrofolate reductase inhibitor.
    Griffin RJ; Stevens MF; Sansom CE
    Anticancer Drug Des; 1990 May; 5(2):201-11. PubMed ID: 2357265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Rosowsky A; Papoulis AT; Queener SF
    J Med Chem; 1998 Mar; 41(6):913-8. PubMed ID: 9526565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
    Gangjee A; Elzein E; Queener SF; McGuire JJ
    J Med Chem; 1998 Apr; 41(9):1409-16. PubMed ID: 9554874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of chicken liver dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines. A quantitative structure-activity relationship and graphics analysis.
    Selassie CD; Fang ZX; Li RL; Hansch C; Klein T; Langridge R; Kaufman BT
    J Med Chem; 1986 May; 29(5):621-6. PubMed ID: 3701780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening.
    Wyss PC; Gerber P; Hartman PG; Hubschwerlen C; Locher H; Marty HP; Stahl M
    J Med Chem; 2003 Jun; 46(12):2304-12. PubMed ID: 12773035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrimethamin-resistant Plasmodium falciparum lack cross-resistance to methotrexate and 2,4-diamino-5-(substituted benzyl) pyrimidines.
    Walter RD; Bergmann B; Kansy M; Wiese M; Seydel JK
    Parasitol Res; 1991; 77(4):346-50. PubMed ID: 1866423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.